TIDMPRTC
PureTech Health PLC
09 July 2021
9 July 2021
PureTech Health plc
PureTech Founded Entity Vor Biopharma Announces Collaboration
with Janssen to Develop Engineered Hematopoietic Stem Cell
Transplants Combined with a Bi-Specific Antibody Therapy for Acute
Myeloid Leukemia (AML)
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company, is pleased to
note that its Founded Entity, Vor Biopharma (Nasdaq: VOR) ("Vor"),
announced the formation of a collaboration with Janssen Biotech,
Inc. ("Janssen"), one of the Janssen Pharmaceutical Companies of
Johnson & Johnson. The agreement was facilitated by Johnson
& Johnson Innovation.
Under the terms of the collaboration, Vor Biopharma will
investigate the combination of these two technologies into a
treatment solution, pairing Vor's "invisible" eHSC transplant
platform with one of Janssen's bi-specific antibodies in
development for acute myeloid leukemia (AML). The collaboration
agreement provides that each company retains all rights and
ownership to their respective programs and platforms.
The full text of the announcement from Vor is as follows:
Vor Biopharma Announces Collaboration with Janssen to Develop
Engineered Hematopoietic Stem Cell Transplants Combined With a
Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)
CAMBRIDGE, Mass., July 08, 2021 - Vor Biopharma (Nasdaq: VOR or
the Company), a cell therapy company pioneering engineered
hematopoietic stem cell (eHSC) therapies combined with targeted
therapies for the treatment of cancer, today announced the
formation of a collaboration with Janssen Biotech, Inc.
("Janssen"), one of the Janssen Pharmaceutical Companies of Johnson
& Johnson. The agreement was facilitated by Johnson &
Johnson Innovation.
Under the terms of the collaboration, Vor Biopharma will
investigate the combination of these two technologies into a
treatment solution, pairing Vor's "invisible" eHSC transplant
platform with one of Janssen's bi-specific antibodies in
development for acute myeloid leukemia (AML).
"We are thrilled to enter into this collaboration with Janssen
as we continue to explore our platform's potential to pair with a
broad spectrum of targeted therapy modalities for the treatment of
patients with blood cancer," said Tirtha Chakraborty, PhD, Vor's
Chief Scientific Officer. "We believe this unique combination will
leverage each technology's strengths, while protecting patients
against off-target effects of these powerful immunotherapies."
The collaboration agreement provides that each company retains
all rights and ownership to their respective programs and
platforms.
About Vor Biopharma
Vor Biopharma is a cell therapy company that aims to transform
the lives of cancer patients by pioneering engineered hematopoietic
stem cell (eHSC) therapies to create next-generation,
treatment-resistant transplants that unlock the potential of
targeted therapies. By removing biologically redundant proteins
from eHSCs, we design these cells and their progeny to be
treatment-resistant to complementary targeted therapies, thereby
enabling these therapies to selectively destroy cancer cells while
sparing healthy cells.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. The words "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "plan," "potential," "project,"
"should," "target," "will," "would," and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
Forward-looking statements in this press release include the
Company's statements regarding its platform's potential to treat
patients suffering from acute myeloid leukemia. The Company may not
actually achieve the plans, intentions, or expectations disclosed
in these forward-looking statements, and you should not place undue
reliance on these forward-looking statements. Actual results or
events could differ materially from the plans, intentions and
expectations disclosed in these forward-looking statements as a
result of various factors, including: uncertainties inherent in the
initiation and completion of preclinical studies and clinical
trials and clinical development of the Company's product
candidates; availability and timing of results from preclinical
studies and clinical trials; whether interim results from a
clinical trial will be predictive of the final results of the trial
or the results of future trials; expectations for regulatory
approvals to conduct trials or to market products and availability
of funding sufficient for the Company's foreseeable and
unforeseeable operating expenses and capital expenditure
requirements. These and other risks are described in greater detail
under the caption "Risk Factors" included in the Company's most
recent annual or quarterly report and in other reports the Company
has filed or may file with the Securities and Exchange Commission.
Any forward-looking statements contained in this press release
speak only as of the date hereof, and the Company expressly
disclaims any obligation to update any forward-looking statements,
whether because of new information, future events or otherwise,
except as may be required by law.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercializing highly
differentiated medicines for devastating diseases, including
inflammatory, fibrotic and immunological conditions, intractable
cancers, lymphatic and gastrointestinal diseases and neurological
and neuropsychological disorders, among others. The Company has
created a broad and deep pipeline through the expertise of its
experienced research and development team and its extensive network
of scientists, clinicians and industry leaders. This pipeline,
which is being advanced both internally and through PureTech's
Founded Entities, is comprised of 26 therapeutics and therapeutic
candidates, including two that have received FDA clearance and
European marketing authorization, as of the date of PureTech's most
recently filed Annual Report on Form 20-F. All of the underlying
programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and
then advanced by the PureTech team through key validation points
based on the Company's unique insights into the biology of the
brain, immune and gut, or BIG, systems and the interface between
those systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, expectations regarding the collaboration between Vor and
Janssen, expectations regarding the potential combination of the
Vor and Janssen technologies into a treatment solution ,
expectations regarding the potential benefits to patients from the
collaboration and those risks and uncertainties described in the
risk factors included in the regulatory filings for PureTech Health
plc. These forward-looking statements are based on assumptions
regarding the present and future business strategies of the company
and the environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors EU media
Allison Mead Talbot Ben Atwell, Rob Winder
+1 617 651 3156 +44 (0) 20 3727 1000
amt@puretechhealth.com ben.atwell@FTIconsulting.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAKZGGNRRKGMZM
(END) Dow Jones Newswires
July 09, 2021 07:00 ET (11:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024